Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.55 |
| ▸ | CA12 | O43570 | 3/20 | 0.53 |
| ▸ | CA1 | P00915 | 3/20 | 0.53 |
| ▸ | CA2 | P00918 | 3/20 | 0.53 |
| ▸ | CA4 | P22748 | 3/20 | 0.53 |
| ▸ | CA7 | P43166 | 3/20 | 0.53 |
| ▸ | CA9 | Q16790 | 3/20 | 0.53 |
| ▸ | DRD2 | P14416 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2001966 | 0.87 | ALDH1A1 (0.60) | ALDH1A1KDM4ECA12CA1CA2 | |
| SCHEMBL2301058 | 0.86 | CKS1B (0.60) | ALDH1A1KDM4ECA12CA1CA2 | |
| SCHEMBL8059749 | 0.84 | ALDH1A1 (0.63) | ALDH1A1KDM4ECA12CA1CA2 | |
| SCHEMBL3156627 | 0.83 | ALDH1A1 (0.54) | ALDH1A1KDM4ECA12CA1CA2 | |
| SCHEMBL13449930 | 0.83 | LMNA (0.57) | ALDH1A1KDM4ECA12CA1CA2 | |
| Hydrochloric Acid SCHEMBL2891558 | 0.82 | ALDH1A1 (0.53) | ALDH1A1KDM4ECA12CA1CA2 | |
| SCHEMBL19652126 | 0.82 | CKS1B (0.63) | ALDH1A1KDM4ECA12CA1CA2 | |
| SCHEMBL19652276 | 0.82 | LMNA (0.59) | ALDH1A1KDM4ECA12CA1CA2 | |
| SCHEMBL4233141 | 0.82 | ALDH1A1 (0.55) | ALDH1A1KDM4ECA12CA1CA2 | |
| SCHEMBL13890887 | 0.81 | LMNA (0.55) | ALDH1A1KDM4ECA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1805181-B1 | PURINE DERIVATIVES FOR USE AS ADENOSIN A-2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2012-08-29 | — | — | EP | disclosed |
| US-8163754-B2 | inflammatory or obstructive airways diseases; in combination with an antiinflammatory, bronchodilatory, antihistamine or anti-tussive; N-[4-(6-Amino-2-phenethylamino-purin-9-yl)-2,3-dihydroxy-cyclopentyl]-propionamide | NOVARTIS AG (CH) | 2012-04-24 | — | — | US | disclosed |
| US-20080200483-A1 | Purine Derivatives for Use as Adenosin A-2A Receptor Agonists | NOVARTIS AG (CH) | 2008-08-21 | — | — | US | disclosed |
| WO-2007121921-A2 | PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2007-11-01 | — | — | WO | disclosed |
| CN-1599745-A | Crystalline forms of ribofuranosyluronamide derivatives: human adenosine A2αReceptor agonists | PFIZER LTD (US) | 2005-03-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200483-A1 | Purine Derivatives for Use as Adenosin A-2A Receptor Agonists | ADORA2A, ADORA1, ADORA3 | ALDH1A1 918/4885KDM4E 4719/4885CA12 4138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.